Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2021

20.08.2021 | comment

The double-edged sword of immune checkpoint inhibition in advanced staged thymic epithelial tumours

verfasst von: MD PhD Wolfgang Jungraithmayr

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Evidence for optimal treatment of thymic epithelial tumours (TET) in advanced stages is limited due to the overall rarity of these tumours. To date, the standard treatment for inoperable and advanced diseases is still chemotherapy. However, with the introduction of immune checkpoint inhibitors (ICIs), new opportunities for the treatment of advanced staged thymomas and thymic carcinomas (TC) became available. ICIs have been proven to show good antitumour activity, at the same time displaying a critical immune-mediated toxicity profile. Here, we discuss the current role of ICI therapy using the example of a patient with a type B2/3 thymoma and point out the double-sided effect of ICI treatment in thymomas or thymic carcinomas. …
Literatur
1.
Zurück zum Zitat Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Cancer Treat Res. 2015;88:154–9. Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Cancer Treat Res. 2015;88:154–9.
2.
Zurück zum Zitat Bedekovics J, Beke L, Mokanszki A, et al. Programmed death-ligand 1 (PD-L1) expression in Thymic epithelial tumors. Appl Immunohistochem Mol Morphol. 2020;28:1–9. CrossRef Bedekovics J, Beke L, Mokanszki A, et al. Programmed death-ligand 1 (PD-L1) expression in Thymic epithelial tumors. Appl Immunohistochem Mol Morphol. 2020;28:1–9. CrossRef
3.
Zurück zum Zitat Weissferdt A, Fujimoto J, Kalhor N, et al. Expression of PD‑1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017;30:826–33. CrossRef Weissferdt A, Fujimoto J, Kalhor N, et al. Expression of PD‑1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017;30:826–33. CrossRef
4.
Zurück zum Zitat Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19:347–55. CrossRef Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19:347–55. CrossRef
5.
Zurück zum Zitat Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed Thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37:2162–70. CrossRef Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed Thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37:2162–70. CrossRef
6.
Zurück zum Zitat Rajan A, Heery CR, Thomas A, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7:269. CrossRef Rajan A, Heery CR, Thomas A, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7:269. CrossRef
7.
Zurück zum Zitat Shen L, Chen H, Wei Q. Immune-therapy-related toxicity events and dramatic remission after a single dose of pembrolizumab treatment in metastatic thymoma: a case report. Front Immunol. 2021;12:621858. CrossRef Shen L, Chen H, Wei Q. Immune-therapy-related toxicity events and dramatic remission after a single dose of pembrolizumab treatment in metastatic thymoma: a case report. Front Immunol. 2021;12:621858. CrossRef
8.
Zurück zum Zitat Konstantina T, Konstantinos R, Anastasios K, et al. Fatal adverse events in two thymoma patients treated with anti-PD‑1 immune check point inhibitor and literature review. Cancer Treat Res. 2019;135:29–32. Konstantina T, Konstantinos R, Anastasios K, et al. Fatal adverse events in two thymoma patients treated with anti-PD‑1 immune check point inhibitor and literature review. Cancer Treat Res. 2019;135:29–32.
9.
Zurück zum Zitat Katsuya Y, Horinouchi H, Seto T, et al. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer. 2019;113:78–86. CrossRef Katsuya Y, Horinouchi H, Seto T, et al. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer. 2019;113:78–86. CrossRef
10.
Zurück zum Zitat Merveilleux du Vignaux C, Dansin E, Mhanna L, et al. Systemic therapy in advanced Thymic epithelial tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13:1762–70. CrossRef Merveilleux du Vignaux C, Dansin E, Mhanna L, et al. Systemic therapy in advanced Thymic epithelial tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13:1762–70. CrossRef
11.
Zurück zum Zitat Zander T, Aebi S, Rast AC, et al. Response to pembrolizumab in a patient with relapsing Thymoma. J Thorac Oncol. 2016;11:e147–e9. CrossRef Zander T, Aebi S, Rast AC, et al. Response to pembrolizumab in a patient with relapsing Thymoma. J Thorac Oncol. 2016;11:e147–e9. CrossRef
12.
Zurück zum Zitat Chen Q, Huang DS, Zhang LW, et al. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol. 2018;56:667–71. CrossRef Chen Q, Huang DS, Zhang LW, et al. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol. 2018;56:667–71. CrossRef
13.
Zurück zum Zitat Girard N, Merveilleux du Vignaux C. Systemic treatment for thymic malignancies. Curr Opin Oncol. 2017;29:112–7. CrossRef Girard N, Merveilleux du Vignaux C. Systemic treatment for thymic malignancies. Curr Opin Oncol. 2017;29:112–7. CrossRef
Metadaten
Titel
The double-edged sword of immune checkpoint inhibition in advanced staged thymic epithelial tumours
verfasst von
MD PhD Wolfgang Jungraithmayr
Publikationsdatum
20.08.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00737-x